Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, talks about the treatment options for patients with lung cancer who have become resistant to their first-line treatments.
Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, talks about the treatment options for patients with lung cancer who have become resistant to their first-line treatments.
Oxnard says the standard of care is chemotherapy with pemetrexed and platinum based on the IMPRESS trial, which showed a response rate of 32% and a profession-free survival rate (PFS) of 5 to 6 months. He adds that other options for patients are now available, such as afatinib which has a response rate of around 10% and a PFS of about 3 months.
Oxnard also says emerging EGFR inhibitors such as rociletinib and osimertinib could be options for patients as well, depending on the situation.
Gertz Assesses Notable Adverse Events of Talquetamab for Relapsed/Refractory Multiple Myeloma
March 26th 2024During a Case-Based Roundtable event, Morie Gertz, MD, discussed the safety profile of talquetamab as a single agent and in combination with daratumumab in patients with relapsed/refractory multiple myeloma.
Read More
George Discusses Potency of VEGF TKIs in Advanced Renal Cell Carcinoma
March 22nd 2024During a Case-Based Roundtable® event, Saby George, MD, discussed the case of a patient with clear cell renal cell carcinoma who progressed after left nephrectomy followed by treatment with axitinib plus pembrolizumab at recurrence.
Read More